Luminex shares are trading higher after the company reported it received FDA emergency use authorization for ARIES SARS-CoV-2 assay to detect virus responsible for COVID-19 disease. The company sees Q1 sales just over $90 million vs $83.3 million est.
Benzinga Newsdesk